Yuviwel Launch Momentum Builds; COACH Wk78 Supports Combo Thesis

Research evidence excerpt

Not for redistribution without written consent of Morgan Stanley

M

Update

August 6, 2026 06:01 PM GMT

Ascendis Pharma A/S | North America

Morgan Stanley & Co. LLC

Maxwell Skor

Equity Analyst

Yuviwel Launch Momentum

Builds; COACH Wk78 Supports

Combo Thesis

Key Takeaways

ASND announced >170 unique Yuviwel patient enrollments in the US, with >65%

Selena Zhang

Research Associate

Ascendis Pharma A/S (ASND.O, ASND US)

Biotechnology | United States of America

Stock Rating

Industry View

Price target

Shr price, close (Aug 5, 2026)

Mkt cap, curr (mm)

52-Week Range

Overweight

Attractive

$275.00

$244.20

€13,170

$282.15-175.19

approved for reimbursement, through June 30.

ASND completed target enrollment for pivotal reACHin Trial supporting planned

regulatory filings for infants 0 to <2 years of age with achondroplasia.

TransCon CNP+TransCon hGH combination therapy Week 78 data from the Ph2

COACH trial showed durable increase in healthy, proportional growth.

TransCon CNP monotx Week 104 data from the pivotal ApproaCH trial

demonstrated durable improvements in height, body proportionality, and lowerlimb alignment.

Ascendis provides update on Yuviwel US uptake. >170 unique Yuviwel patient

enrollments in the US by ~90 prescribing HCPs, with more than 65% approved for

reimbursement, through June 30 (press release, presentation). The company is

seeing demand from switch, naïve and return-to-treatment patients, which they see

as an indication of significant unmet need and broad-based appeal while pointing to

market expansion. All enrollments through this date reflect patients new to Yuviwel

therapy. Recall, >60 Yuviwel enrollments by more than 35 prescribing healthcare

providers occurred as of May 1 (see our note HERE, and HERE). ASND completed

target enrollment for pivotal reACHin trial supporting planned regulatory filings for

infants 0 to <2 years of age with achondroplasia, which we expect to provide further

expansion. We are encouraged by early uptake for the Yuviwel launch and

continuing data supporting durable benefit. We await initial determination by

the judge in the BMRN v. ASND ITC case by 8/21, where we continue to expect

…